ECE2018 Guided Posters Pituitary Basic (8 abstracts)
E-cadherin expression is associated with the response to somatostatin analogues in patients with acromegaly
David A Cano 1 , Eva Venegas-Moreno 1 , Noelia Gros-Herguido 1 , Elena Dios 1 , Alvaro Flores-Martinez 1 , Natividad Gonzalez 1 , Ainara Madrazo-Atutxa 1 , Eugenio Cardenas 2 , Ariel Kaen 2 , Justo P Castaño 3 , Raul M Luque 3 & Alfonso Soto-Moreno 1
1Unidad de Gestión de Endocrinología y Nutrición. Instituto de Biomedicina de Sevilla (IBiS), Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Sevilla, Spain; 2Servicio de Neurocirugía. Hospital Virgen del Rocío, Sevilla, Spain; 3Departamento de Biologia Celular, Fisiologia e Inmunologia. Universidad de Cordoba, Hospital Universitario Reina Sofía, Instituto Maimonides de Investigacion Biomedica de Cordoba (IMIBIC), Campus de Excelencia Internacional Agroalimentario (ceiA3), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERObn), Cordoba, Spain.
Aim: To assess whether E-cadherin expression levels in somatotropinomas were associated with the response to somatostatin analogues (SSAs) therapy in patients with acromegaly.
Methods: In this retrospective study, 56 acromegaly patients that underwent transsphenoidal surgery were evaluated. All patients were treated preoperatively with SSAs (octreotide or lanreotide) for at least 6 months. Responsiveness to SSAs was evaluated by percent IGF-1 reduction after 3 and 6 months of treatment. Quantitative PCR was used to measure the expression of somatostatin receptors (SSTR1-SSTR5) and dopamine receptors (DRD1-DRD5). The expression of E-cadherin was evaluated by immunohistochemistry. Clinical and pathological variables were collected to evaluate potential associations between these variables and E-cadherin expression.
Results: 28 of the somatotropinomas examined were found negative for E-cadherin. The remaining adenomas displayed moderate (10) or strong (18) immunoreactivity for E-cadherin and were analyzed as one single group. No statistically significant differences were observed between E-cadherin negative and positive adenomas regarding age, tumor invasion and GH and IGF1 levels at diagnosis. E-cadherin negative somatotropinomas were larger and more prevalent in women than in men. Almost all E-cadherin negative somatotropinomas were sparsely granulated adenomas. The IGF-1 per cent reduction after 3 and 6 months of SSAs treatment was significantly in E-cadherin negative adenomas compared with moderate/high E-cadherin adenomas. At 3 months of treatment, the median IGF-1 per cent reduction for adenomas negative for E-cadherin was 4.1 and 44.2 for adenomas positive por E-cadherin. At 6 months of treatment, the median IGF-1 per cent reduction for adenomas negative for E-cadherin was 8.9 and 49.8 for adenomas positive for E-cadherin. E-cadherin negative adenomas displayed lower SSTR1 and DRD4 expression levels.
Conclusions: In our series, a poor response to treatment with SSAs in patients with acromegaly is associated with absence of E-cadherin accumulation in somatotropinomas.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more